The American biotech company Thermo Fisher Scientific Inc. has signed an agreement to acquire Clario Holdings Inc. for $8.9 billion. This is reported in the Thermo Fisher press release.
Thermo Fisher will buy Clario's assets from a group of shareholders that includes private equity firms Nordic Capital, Astorg Partners, Novo Holdings and Cinven.
The deal will be one of the largest in the field of biotechnology and will provide Thermo Fisher with access to Clario, which plays a key role in managing clinical data from drug trials.
The agreement also provides for potential payments of up to $525 million based on future performance.
Clario's revenue will amount to $1.25 billion by providing drug testing services in 100 countries and obtaining more than 700 regulatory approvals for medicines worldwide.
Thermo Fisher previously acquired the filtration division from Solventum Corp. for $4.1 billion and clinical research service provider PPD Inc. for $17.4 billion.
Thermo Fisher Scientific Inc. is an American biotech company in the field of clinical research. The company supplies analytical instruments for clinical development. The headquarters is located in Waltham, Massachusetts.
Clario is an American technology company in the field of clinical research data processing. The company provides clinical services to biopharmaceutical companies and healthcare organizations. The company is headquartered in Philadelphia, California. Clario was formed in 2021 as part of the merger of the medical technology groups ERT and Bioclinica.
Read also in our Telegram channel "Mergers and acquisitions. AK&M».
